نبذة مختصرة : Dengue Hemorrhagic Fever (DHF) as one of the most common infectious diseases in the world is still a major concern even though the incidence and mortality rates have decreased. The study objective is to determine hematological examination results and the speed of recovery of DHF patients reviewed according to age, gender, BMI, degree of DHF, and duration of fever before being treated. This was cross-sectional study using secondary data from medical records of 193 DHF patients treated from year 2019 to 2020. In 193 patients, before being admitted to the hospital, the patient had an average fever for 4.12±1.16 days with an average 4.69±1.2 days of hospitalization. Hematological test on hospital admission showed the average platelet value was 83.06±28.74 x103 cells/µL with 187 (96.9%) patients had platelet values below the normal value. Average leukocyte count was 4.13±2.01 x 103 cells/µL with 126 (65.3%) patients having a leukocyte value below the normal value. Average hematocrit value was 40.31±4.96% with 113 (58.6%) patients had normal hematocrit values. The duration of hospitalization for DHF patients had a significant difference when viewed according to age (p=0.000), BMI (p=0.000), and duration of fever before being treated (p=0.000). The mean platelet values were significantly different when compared according to the duration of fever before being treated (p=0.018). The mean leukocyte values were significantly different when compared according to age (p=0.007) and gender (p=0.008). The mean hematocrit value was significantly different when compared according to age (p=0.000) and gender (p=0.008). Keywords: Dengue hemorrhagic fever, hematological examination, duration of hospitalization ; ABSTRAK Demam Berdarah Dengue (DBD) sebagai salah satu penyakit infeksi yang paling sering terjadi di dunia masih menjadi perhatian utama meskipun angka insiden dan angka kematiannya telah menurun. Penelitian ini bertujuan untuk mengetahui karakteristik hasil pemeriksaan hematologi dan kecepatan pemulihan pasien DBD ...
No Comments.